Intrahepatic Cholestasis of Pregnancy (Obstetric Cholestasis)

1. Clinical Overview

Summary

Intrahepatic cholestasis of pregnancy (ICP), also known as obstetric cholestasis, is the most common pregnancy-specific liver disorder, characterised by pruritus and elevated serum bile acids. [1,2] It typically presents in the third trimester (although can occur earlier) and resolves spontaneously within 48 hours to 2 weeks postpartum. [3]

The condition is caused by impaired hepatocellular bile acid transport, exacerbated by high oestrogen and progesterone levels in pregnancy, often with an underlying genetic predisposition. [4,5] The pathognomonic feature is intense pruritus without a primary rash, most pronounced on the palms and soles, and characteristically worse at night. [6]

The primary clinical concern is the unpredictable risk of sudden intrauterine death, which correlates directly with maternal serum bile acid levels. [7,8] Risk is minimal at bile acids less than 40 μmol/L but increases substantially at levels > 100 μmol/L. [7] This has led to risk-stratified management protocols involving ursodeoxycholic acid (UDCA) therapy, intensive fetal surveillance, and planned early delivery between 37-39 weeks' gestation depending on bile acid severity. [9,10]

Recent evidence from the PITCHES randomised controlled trial challenged the efficacy of UDCA for improving perinatal outcomes, though symptomatic benefit for maternal pruritus remains recognised. [11] Current management emphasises bile acid monitoring, symptom relief, and appropriately timed delivery. [9]

Key Facts

Clinical Pearls

"Itch Without Rash": The hallmark of ICP is pruritus without a primary dermatological eruption. Scratch marks (excoriations) are secondary. Any pregnant woman with unexplained itching requires bile acid measurement. [6]

"Palms and Soles at Night": The classic distribution. Patients describe desperate nocturnal pruritus preventing sleep, often leading to cold water immersion or ice application for temporary relief. [6]

"Bile Acids > 100 = Red Alert": While stillbirth risk exists at all elevated bile acid levels, it increases substantially > 100 μmol/L (3-5% stillbirth risk). Consider delivery from 36 weeks in severe cases. [7,8]

"Resolves Postpartum = Diagnostic": Symptoms and biochemistry that fail to resolve within 2 weeks of delivery suggest alternative diagnoses (chronic liver disease, PFIC carrier state). [3]

"PITCHES Changed Practice": The 2019 PITCHES RCT showed UDCA did not reduce adverse perinatal outcomes. UDCA is now primarily for maternal symptom relief, not fetal indication. [11]

"Earlier Onset = Consider Genetics": ICP presenting before 28 weeks, particularly in primigravidae or with family history, should prompt consideration of genetic testing for ABCB4/ATP8B1/ABCB11 variants. [5,12]

---

2. Epidemiology

Incidence and Prevalence

Intrahepatic cholestasis of pregnancy affects 0.5-1.5% of pregnancies in the United Kingdom and Western Europe. [1,2] However, incidence varies dramatically by ethnicity and geography:

Seasonal Variation

Some studies report higher incidence in winter months, possibly related to lower vitamin D levels, though this remains controversial. [16]

Risk Factors

Demographic Factors

• Parity: Can affect primigravidae or multigravidae equally
• Age: Slight increase with maternal age > 35 years
• BMI: No consistent association, though some data suggest higher risk in obesity
• Smoking: No clear protective or causative effect

---

3. Aetiology and Pathophysiology

Molecular Basis

Exam Detail: Intrahepatic cholestasis of pregnancy results from impaired hepatocellular transport of bile acids from hepatocytes into bile canaliculi, leading to accumulation of bile acids in maternal serum, tissues, and placental circulation. [4,5]

Bile Acid Transporters

Normal bile acid homeostasis requires coordinated function of hepatocellular transport proteins:

Hormonal Modulation

Oestrogen and progesterone metabolites (particularly sulphated progesterone) inhibit bile acid transporters, particularly BSEP and MDR3. [4,19] In susceptible women (genetic variants, reduced transporter reserve), the physiological hormone surge of the third trimester overwhelms hepatocellular bile acid export capacity. [4]

This explains:

• Third trimester onset (peak oestrogen/progesterone)
• Recurrence with combined oral contraceptives (oestrogen exposure)
• Higher risk in twin pregnancies (elevated hormone levels)

Genetic Predisposition

15-20% of ICP cases have identifiable mutations in ABCB4, ATP8B1, or ABCB11. [5,12] These mutations are often heterozygous; pregnancy provides the "second hit" that unmasks cholestasis. [20]

Homozygous mutations in these genes cause progressive familial intrahepatic cholestasis (PFIC) in childhood, a severe condition leading to cirrhosis. [20] Women with ICP may be heterozygous carriers of PFIC mutations.

Familial clustering is common, particularly in Chilean and South Asian populations, where founder mutations exist. [14]

Pathophysiological Consequences

Maternal Effects

Elevated bile acids accumulate in:

• Skin: Pruritus (mechanism unclear; may involve TGR5 receptor activation on sensory neurons) [21]
• Liver: Mild hepatocellular injury (elevated transaminases)
• Enterohepatic circulation: Malabsorption of fat-soluble vitamins (particularly vitamin K, though clinically significant deficiency is rare)

Fetal Effects

Bile acids cross the placenta and accumulate in fetal circulation. [22] Mechanisms of fetal harm include:

1. Cardiac Arrhythmogenesis

   • Bile acids (particularly taurocholate) induce abnormal calcium handling in fetal cardiomyocytes [22,23]
   • Predispose to fetal bradyarrhythmias and sudden cardiac arrest
   • Explains sudden, unpredictable stillbirth without preceding CTG abnormalities [23]

2. Placental Vasoconstriction

   • Bile acids cause acute vasoconstriction of chorionic plate vessels [24]
   • Reduces placental perfusion
   • May contribute to acute hypoxia

3. Colonic Hypermotility

   • Bile acids stimulate fetal colonic motility [25]
   • Increases meconium passage in utero
   • Risk of meconium aspiration syndrome

4. Preterm Labour

   • Bile acids increase myometrial sensitivity to oxytocin [26]
   • Spontaneous preterm birth occurs in 10-15% ICP cases [8]

---

4. Clinical Presentation

Symptoms

Pruritus (95-100% cases) [6]

The pathognomonic symptom of ICP is intense, generalised pruritus without a primary rash.

Onset: Typically 28-32 weeks' gestation, but can occur as early as 6-8 weeks (rare) or in second trimester (10% cases). [3]

Earlier onset (before 28 weeks) or presentation in a primigravida should raise suspicion of genetic predisposition. [5]

Other Symptoms (Less Common)

Important: ICP does NOT cause:

• Acute abdominal pain (consider HELLP, acute fatty liver, gallstones)
• High fever (consider sepsis, cholangitis)
• Severe vomiting (consider hyperemesis, acute fatty liver)

Resolution Postpartum

• Pruritus: Resolves within 48 hours to 1 week after delivery [3]
• Bile acids: Normalise within 1-2 weeks postpartum [3]
• Transaminases: Return to normal within 2-6 weeks [3]

Failure to resolve within 2 weeks should prompt investigation for chronic liver disease, PFIC carrier state, or alternative diagnosis.

---

5. Clinical Examination

General Inspection

• Skin: Excoriations, scratch marks (linear, often infected secondarily); lichenification in severe cases
• No primary rash: Absence of urticarial wheals, vesicles, papules, or erythematous plaques (key differentiator from other pregnancy dermatoses)
• Jaundice: Mild scleral icterus in 10-15% cases [6]
• Pallor: Not a feature unless coincident anaemia

Abdominal Examination

• Uterus: Appropriate size for gestational age
• Tenderness: Non-tender; right upper quadrant tenderness should prompt ultrasound (exclude biliary pathology)
• Hepatomegaly: Not a feature of ICP; palpable liver edge suggests alternative diagnosis
• Fetal movements: Initially normal; reduced movements are a red flag (fetal compromise)

Signs NOT Expected in ICP

Examination Viva Scenario

Exam Detail: Examiner: "A 32-year-old woman at 34 weeks' gestation presents with severe itching. Describe your examination approach."

Model Answer:

"I would conduct a systematic examination to:

1. Confirm pruritus without primary rash:

   • Inspect skin for excoriations (secondary) vs primary dermatological eruption
   • Focus on palms and soles (typical distribution in ICP)
   • Note absence of wheals, vesicles, or papules

2. Assess for jaundice:

   • Scleral icterus
   • Skin tone (though unreliable)

3. Abdominal examination:

   • Confirm appropriate fundal height
   • Exclude right upper quadrant tenderness (biliary pathology)
   • Exclude hepatosplenomegaly (chronic liver disease)
   • Assess fetal movements (CTG if reduced)

4. Exclude pre-eclampsia:

   • Blood pressure
   • Check urine dipstick for proteinuria

5. General examination:

   • Exclude signs of chronic liver disease (spider naevi, palmar erythema, ascites)
   • Exclude encephalopathy (AFLP)

Next steps: Arrange urgent serum bile acids and liver function tests. If bile acids > 10 μmol/L, diagnose ICP and initiate risk-stratified management."

---

6. Differential Diagnosis

Pregnancy-Specific Liver Disorders

Pregnancy Dermatoses

Non-Pregnancy-Specific Liver Disease

Comparison Table: ICP vs HELLP vs AFLP

---

7. Investigations

First-Line Investigations

Serum Bile Acids (Diagnostic)

• Diagnostic criterion: > 10 μmol/L in the presence of pruritus [7,9]
• Normal pregnancy: less than 10 μmol/L (usually less than 6 μmol/L)
• Timing: Fasting or non-fasting both acceptable; fasting may reduce variability
• Repeat: Weekly monitoring once diagnosed (bile acids can rise rapidly) [9]

Risk Stratification by Bile Acid Level: [7,8]

Evidence: Ovadia et al. (2019) meta-analysis of 22,617 pregnancies demonstrated direct correlation between bile acid levels and adverse outcomes. [7]

Liver Function Tests

Important: Transaminases may rise before bile acids in early disease. [6] If clinical suspicion is high with normal bile acids, repeat in 1 week.

Exclude Alternative Diagnoses

Fetal Monitoring

Critical Point: CTG monitoring in ICP has low sensitivity for stillbirth, as intrauterine death is often acute and unpredictable without preceding CTG abnormalities. [35] The PITCHES trial found no benefit of intensive CTG surveillance. [11]

Genetic Testing (Selective)

Consider genetic screening (ABCB4, ATP8B1, ABCB11) if: [5,12]

• Early-onset ICP (before 28 weeks)
• Severe ICP (bile acids > 100 μmol/L)
• Strong family history (multiple affected relatives)
• Persistence of LFT abnormalities > 8 weeks postpartum (suggests chronic cholestatic liver disease)
• Primigravida with severe ICP (no obvious pregnancy-hormone trigger in previous pregnancies)

Implications:

• Counselling for future pregnancies
• Screening family members
• Risk of chronic liver disease post-pregnancy (rare, but reported with compound heterozygous mutations)

---

8. Management

Management Principles

1. Confirm diagnosis: Bile acids > 10 μmol/L with pruritus
2. Risk stratification: Classify by bile acid level (mild less than 40, moderate 40-99, severe ≥100 μmol/L)
3. Maternal symptom relief: UDCA, emollients, antihistamines
4. Fetal surveillance: Weekly bile acids, CTG surveillance, maternal fetal movement monitoring
5. Plan delivery: Risk-stratified timing (37-39 weeks depending on bile acid level) [9,10]
6. Postnatal follow-up: Confirm resolution, counsel recurrence risk

Maternal Treatment

Ursodeoxycholic Acid (UDCA)

Mechanism: Hydrophilic bile acid that:

• Displaces toxic hydrophobic bile acids (chenodeoxycholic acid, deoxycholic acid)
• Improves hepatocellular bile acid transport
• Reduces pruritus
• May reduce maternal bile acid levels

Dosing: [9,11]

• 10-15 mg/kg/day in 2-3 divided doses (e.g., 500 mg TDS for 70 kg woman)
• Maximum dose: 2000 mg/day

Evidence:

• PITCHES Trial (2019): Large RCT (n=605) showed UDCA did not reduce composite adverse perinatal outcome (stillbirth, preterm birth, neonatal unit admission) compared to placebo. [11]
• However, UDCA reduced maternal bile acids by 30-50% and improved pruritus in 50-70% women. [11,36]

Current Recommendation: [9,10]

• UDCA is recommended for maternal symptom relief (pruritus)
• Not primarily for fetal indication (per PITCHES trial evidence)
• Offer to women with ICP; counsel regarding evidence limitations
• Safe in pregnancy; no evidence of fetal harm

Symptomatic Relief

Not Recommended:

• Cholestyramine: Poorly tolerated (nausea, constipation), minimal efficacy, binds fat-soluble vitamins [38]
• Topical corticosteroids: Ineffective (no inflammatory dermatosis)

Vitamin K Supplementation

Indication: Prolonged cholestasis with jaundice or elevated bilirubin > 50 μmol/L

• Risk of vitamin K deficiency (fat-soluble vitamin malabsorption)
• Risk of maternal postpartum haemorrhage (rare)
• Risk of neonatal haemorrhagic disease (theoretical)

Dosing:

• Oral vitamin K 10 mg daily from diagnosis until delivery [9]

Evidence: Weak; vitamin K deficiency rarely clinically significant in modern practice, but low-risk intervention. [9]

Fetal Monitoring and Surveillance

Critical Point: Advise women that fetal movements are the most important indicator of fetal wellbeing and to attend for immediate assessment if movements reduce. [9]

Delivery Timing

Balancing risk: Stillbirth risk (continues in utero) vs prematurity risk (iatrogenic)

Evidence-Based Timing: [9,10]

Mode of Delivery:

• Induction of labour preferred (no indication for routine caesarean section)
• Vaginal delivery safe unless obstetric contraindications
• Increased risk of meconium-stained liquor (20-30%) [8]
• CTG monitoring in labour recommended

Delivery Planning:

• Consultant-led unit
• Paediatric team aware (risk of meconium aspiration)
• Corticosteroids for fetal lung maturation if delivery planned less than 38 weeks (particularly less than 37 weeks)

Management Algorithm

┌─────────────────────────────────────────────────────────────────┐
│         INTRAHEPATIC CHOLESTASIS OF PREGNANCY                   │
│                  MANAGEMENT PATHWAY                             │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  DIAGNOSIS:                                                     │
│  • Pruritus + Bile Acids > 10 μmol/L                            │
│  • Exclude alternative diagnoses (HELLP, AFLP, hepatitis)      │
│                                                                 │
│  ↓                                                              │
│                                                                 │
│  RISK STRATIFICATION:                                           │
│  • Bile Acids less than 40: MILD                                        │
│  • Bile Acids 40-99: MODERATE                                  │
│  • Bile Acids ≥100: SEVERE                                     │
│                                                                 │
│  ↓                                                              │
│                                                                 │
│  MATERNAL TREATMENT:                                            │
│  • UDCA 10-15 mg/kg/day (500 mg TDS typical dose)             │
│  • Emollients (aqueous cream, menthol cream)                   │
│  • Chlorphenamine 4 mg TDS-QDS                                 │
│  • Vitamin K 10 mg OD if bilirubin > 50 μmol/L                 │
│                                                                 │
│  ↓                                                              │
│                                                                 │
│  MONITORING:                                                    │
│  • Weekly bile acids and LFTs                                  │
│  • CTG twice weekly from diagnosis                            │
│  • Ultrasound growth every 2-4 weeks                           │
│  • Maternal fetal movement monitoring (MOST IMPORTANT)         │
│                                                                 │
│  ↓                                                              │
│                                                                 │
│  DELIVERY PLANNING:                                             │
│  • Bile Acids less than 40: Deliver 38-39 weeks                        │
│  • Bile Acids 40-99: Deliver 37-38 weeks                      │
│  • Bile Acids ≥100: Deliver 36-37 weeks (individualised)      │
│  • Induction of labour (vaginal delivery preferred)            │
│  • Corticosteroids if delivery less than 38 weeks                       │
│                                                                 │
│  ↓                                                              │
│                                                                 │
│  POSTNATAL:                                                     │
│  • Symptoms resolve within 48 hours to 2 weeks                │
│  • Repeat LFTs at 6-8 weeks (confirm resolution)              │
│  • Counsel recurrence risk (45-90%)                            │
│  • Avoid oestrogen-containing contraception (COC)              │
│  • Genetic testing if severe/early onset                       │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘

---

9. Complications

Fetal Complications

Stillbirth Mechanism:

Exam Detail: Stillbirth in ICP is characteristically sudden and unpredictable, often occurring in previously well-grown fetuses without preceding CTG abnormalities. [23,35] Proposed mechanisms include:

1. Cardiac Arrhythmia: Taurocholate (predominant bile acid) induces abnormal calcium handling in fetal cardiomyocytes, leading to bradyarrhythmias and asystole. [22,23]

2. Acute Placental Vasoconstriction: Bile acids cause acute constriction of chorionic plate vessels, reducing placental perfusion and causing acute fetal hypoxia. [24]

3. Sudden Hypoxic Event: Combination of cardiac and placental effects leads to rapid fetal decompensation without warning.

This explains why:

• CTG has poor predictive value in ICP (normal CTG does not exclude risk)
• Stillbirths occur in the third trimester (peak bile acid levels)
• Risk is directly proportional to bile acid levels (dose-response relationship)

Maternal Complications

No Increased Risk Of:

• Maternal liver failure (ICP is self-limiting)
• Chronic liver disease (unless underlying genetic cholestatic disorder)
• Maternal mortality (not a life-threatening condition for mother)

---

10. Prognosis and Outcomes

Maternal Outcomes

Immediate (Pregnancy)

• Resolution: Pruritus resolves within 48 hours to 1 week postpartum; bile acids normalise within 1-2 weeks; transaminases return to normal within 2-6 weeks. [3]
• Delivery: Most women deliver successfully vaginally with induction of labour.
• Quality of life: Severe pruritus causes significant sleep disturbance, psychological distress, and reduced quality of life during pregnancy.

Recurrence

• Subsequent pregnancies: 45-90% recurrence risk (higher in women with severe ICP, genetic mutations, or strong family history). [13]
• Recurrence pattern: Often earlier onset and more severe in subsequent pregnancies. [13]
• Oestrogen exposure: 30-50% women report pruritus with combined oral contraceptive pill (COC); avoid oestrogen-containing contraception. [40]

Long-Term Maternal Health

• Chronic liver disease: Small increased risk in women with ICP, particularly if underlying genetic mutation (ABCB4/ATP8B1/ABCB11). [20]
• Hepatobiliary disease: Slightly increased lifetime risk of gallstones, hepatitis C sequelae. [17]
• Cardiovascular/metabolic disease: Emerging evidence suggests women with ICP may have increased long-term risk of cardiovascular and metabolic disorders, though causality unclear. [41]

Follow-Up:

• Repeat LFTs at 6-8 weeks postpartum to confirm resolution. [9]
• If LFTs remain abnormal > 8 weeks, investigate for chronic liver disease (ultrasound, autoimmune screen, consider genetic testing).

Fetal/Neonatal Outcomes

With Modern Management

With risk-stratified management (UDCA, weekly monitoring, planned delivery 37-39 weeks): [7,8,10]

Key Point: With appropriate monitoring and planned delivery, the majority of pregnancies affected by ICP have good perinatal outcomes. [7,8]

---

11. Prevention and Counselling

Preconception Counselling

For women with previous ICP:

1. Recurrence risk: 45-90%; often earlier and more severe [13]
2. Genetic testing: Consider if severe ICP, early onset, or family history [5,12]
3. Folic acid: Standard 400 μg daily (5 mg if additional risk factors)
4. Avoid high-risk timing: No evidence to support specific timing of conception
5. Plan early pregnancy: Arrange early ultrasound dating (important for delivery planning)

Antenatal Counselling (After ICP Diagnosis)

1. Natural history: Explain symptoms resolve postpartum; recurrence risk in future pregnancies
2. Fetal risks: Stillbirth risk (proportional to bile acid level); preterm birth risk; need for early delivery
3. Monitoring plan: Weekly bile acids, CTG surveillance, importance of fetal movement monitoring
4. Treatment: UDCA primarily for symptom relief (evidence limitations re: fetal benefit)
5. Delivery planning: Induction of labour 37-39 weeks (depending on bile acid severity)
6. Mental health: Acknowledge anxiety regarding stillbirth; offer psychological support

Postnatal Counselling

1. Resolution: Confirm resolution with LFTs at 6-8 weeks
2. Contraception: Avoid COC (oestrogen-containing); recommend progestogen-only pill, IUD, barrier methods [40]
3. Future pregnancies: 45-90% recurrence; earlier onset likely; recommend specialist antenatal care from early pregnancy
4. Genetic counselling: If severe ICP, early onset, or persistent LFT abnormality, consider genetic testing and counselling

---

12. Guidelines and Evidence

Key Guidelines

1. Royal College of Obstetricians and Gynaecologists (RCOG): Green-top Guideline No. 43: Obstetric Cholestasis (2011; updated 2022). [9]

   • Authoritative UK guidance
   • Risk-stratified management by bile acid level
   • Delivery timing recommendations

2. Society for Maternal-Fetal Medicine (SMFM): Intrahepatic Cholestasis of Pregnancy (Consult Series #53, 2021). [10]

   • US-based guidance
   • Similar risk stratification to RCOG
   • Emphasises shared decision-making for delivery timing

3. European Association for the Study of the Liver (EASL): Clinical Practice Guidelines on the Management of Cholestatic Liver Diseases (2009). [42]

   • Includes ICP in broader cholestatic disease context

Landmark Evidence

PITCHES Trial (2019) [11]

Full Title: Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial

Authors: Chappell LC, et al. Journal: Lancet 2019;394(10201):849-860 PMID: 31378395

Design: Multicentre, double-blind, placebo-controlled RCT Population: 605 women with ICP (bile acids ≥40 μmol/L) Intervention: UDCA 500 mg QDS vs placebo Primary outcome: Composite adverse perinatal outcome (stillbirth, preterm birth, neonatal unit admission)

Results:

• No significant difference in composite outcome: UDCA 54% vs placebo 53% (RR 1.02, 95% CI 0.87-1.19)
• No reduction in stillbirth (UDCA 0.3% vs placebo 0.3%)
• UDCA reduced maternal bile acids by 30-50%
• UDCA improved pruritus (subjective benefit)

Conclusion: UDCA does not improve perinatal outcomes in ICP. Current use is for maternal symptom relief, not fetal indication.

Impact: Changed practice worldwide; UDCA no longer considered "fetal protective therapy."

Ovadia et al. Meta-Analysis (2019) [7]

Full Title: Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers

Authors: Ovadia C, et al. Journal: Lancet 2019;393(10174):899-909 PMID: 30773280

Design: Individual participant data meta-analysis Population: 22,617 pregnancies with ICP across 25 studies

Key Findings:

• Bile acid-dependent stillbirth risk:
  • less than 40 μmol/L: 0.13% (similar to background)
  • 40-99 μmol/L: 1-1.5%
  • ≥100 μmol/L: 3-4%
• Direct dose-response relationship between bile acid level and adverse outcomes
• Preterm birth risk also correlates with bile acid level

Impact: Established bile acid thresholds for risk stratification (40 and 100 μmol/L), now used in international guidelines.

Other Key Evidence

3. Williamson C, et al. Intrahepatic cholestasis of pregnancy. Obstet Gynecol 2014. [PMID: 24901263] [24]

   • Comprehensive review of pathophysiology

4. Dixon PH, et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy. Hum Mol Genet 2000. [PMID: 10814715]

   • Seminal genetic discovery linking ABCB4 to ICP

5. Geenes V, et al. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes. Hepatology 2014. [PMID: 24122873]

   • Risk stratification evidence

---

13. Examination Focus

MRCOG Part 2: Clinical Assessment Viva

Exam Detail: Scenario: "A 34-year-old primigravida at 32 weeks' gestation presents with severe itching of her hands and feet, worse at night. She has no rash. How would you manage this patient?"

Model Answer Structure:

1. Immediate Assessment

• "I would take a focused history to characterise the pruritus: onset, distribution (palms/soles suggests ICP), severity (sleep disruption), presence of primary rash (absent in ICP), associated symptoms (jaundice, dark urine, pale stools)."
• "I would examine for excoriations (secondary), absence of primary dermatological eruption, exclude jaundice, and perform abdominal examination (uterine size, tenderness, fetal movements)."
• "I would check blood pressure and urine dipstick to exclude pre-eclampsia."

2. Investigations

• "Urgent serum bile acids (diagnostic if > 10 μmol/L) and liver function tests."
• "Full blood count, renal function, coagulation screen to exclude HELLP syndrome or AFLP."
• "Viral hepatitis serology (A, B, C, E) to exclude viral hepatitis."
• "Liver ultrasound if atypical features or to exclude biliary obstruction."

3. If ICP Confirmed (Bile Acids > 10 μmol/L)

• "Risk stratify by bile acid level: mild (less than 40), moderate (40-99), or severe (≥100 μmol/L)."
• "Initiate UDCA 10-15 mg/kg/day (500 mg TDS for symptomatic relief; counsel regarding PITCHES trial evidence that UDCA does not reduce perinatal complications)."
• "Symptomatic relief: emollients (aqueous cream, menthol cream), chlorphenamine 4 mg TDS-QDS."
• "Weekly bile acid and LFT monitoring."
• "CTG surveillance twice weekly (though limited predictive value for stillbirth)."
• "Advise woman to monitor fetal movements daily and attend immediately if reduced."
• "Plan delivery: if bile acids less than 40 μmol/L, deliver 38-39 weeks; if 40-99 μmol/L, deliver 37-38 weeks; if ≥100 μmol/L, consider delivery from 36 weeks (individualised, balancing stillbirth vs prematurity risk)."

4. Follow-Up

• "Repeat LFTs at 6-8 weeks postpartum to confirm resolution."
• "Counsel recurrence risk 45-90% in future pregnancies."
• "Advise avoidance of oestrogen-containing contraception."
• "If severe ICP or early onset, consider genetic testing."

Examiner Follow-Up Questions:

Q: "What is the mechanism of stillbirth in ICP?"

• "Bile acids cross the placenta and accumulate in fetal circulation. Taurocholate, the predominant bile acid, causes abnormal calcium handling in fetal cardiomyocytes, predisposing to bradyarrhythmias and sudden cardiac arrest. Additionally, bile acids cause acute vasoconstriction of placental vessels, reducing placental perfusion. These mechanisms result in sudden, unpredictable stillbirth, often without preceding CTG abnormalities."

Q: "Why is CTG surveillance of limited value in ICP?"

• "Stillbirth in ICP is characteristically sudden and acute, resulting from bile acid-induced cardiac arrhythmia rather than progressive placental insufficiency. Therefore, CTG often remains reassuring until a sudden terminal event. The PITCHES trial found no benefit of intensive CTG surveillance in preventing adverse outcomes. Maternal fetal movement monitoring is arguably more important, with immediate assessment if movements reduce."

Q: "A woman with ICP at 36 weeks has bile acids of 120 μmol/L. She declines induction of labour, requesting expectant management until 40 weeks. How do you respond?"

• "I would explain that bile acids ≥100 μmol/L confer a stillbirth risk of 3-5%, which is significantly higher than background risk (~0.1%). I would explain that this risk continues while the pregnancy continues, and delivery is the only definitive treatment. I would discuss the risks of prematurity at 36-37 weeks (respiratory distress, neonatal unit admission) but emphasise that at 36 weeks, neonatal outcomes are generally good, particularly with antenatal corticosteroids."
• "I would use shared decision-making, exploring her concerns about induction and prematurity. I would offer multidisciplinary input (maternal-fetal medicine consultant, neonatologist) to provide balanced information."
• "Ultimately, I would respect her autonomy if she declines, but clearly document the discussion, the risks explained, and her informed decision. I would offer very close surveillance (daily CTG, twice-daily fetal movement monitoring) and arrange urgent review if any concerns."

MRCOG Part 1: SBA Questions

Exam Detail: Question 1:

A 29-year-old woman at 34 weeks' gestation presents with severe pruritus affecting her palms and soles, worse at night. Serum bile acids are 85 μmol/L. Liver function tests show ALT 180 U/L, bilirubin 25 μmol/L. Which of the following is the MOST important reason for planning early delivery?

A. Maternal liver failure B. Fetal cardiac arrhythmia leading to stillbirth C. Neonatal hypoglycaemia D. Maternal postpartum haemorrhage E. Fetal growth restriction

Answer: B. Fetal cardiac arrhythmia leading to stillbirth

Explanation: The primary concern in ICP is stillbirth, caused by bile acid-induced fetal cardiac arrhythmias (abnormal calcium handling in fetal cardiomyocytes) and placental vasoconstriction. Bile acids of 85 μmol/L (moderate-severe range) confer ~1-2% stillbirth risk. ICP does not cause maternal liver failure (self-limiting condition), neonatal hypoglycaemia (seen in AFLP), or fetal growth restriction (uncommon in ICP).

---

Question 2:

The PITCHES trial (2019) demonstrated which of the following regarding ursodeoxycholic acid (UDCA) in intrahepatic cholestasis of pregnancy?

A. UDCA reduces stillbirth risk by 50% B. UDCA significantly reduces composite adverse perinatal outcomes C. UDCA reduces maternal bile acids but does not improve perinatal outcomes D. UDCA increases risk of preterm birth E. UDCA causes fetal hepatotoxicity

Answer: C. UDCA reduces maternal bile acids but does not improve perinatal outcomes

Explanation: The PITCHES RCT (Chappell LC et al., Lancet 2019) showed that UDCA reduced maternal bile acids by 30-50% and improved maternal pruritus, but did NOT significantly reduce the composite adverse perinatal outcome (stillbirth, preterm birth, neonatal unit admission). This changed practice: UDCA is now used primarily for maternal symptom relief, not fetal indication.

---

14. Patient/Layperson Explanation

What is Obstetric Cholestasis (Intrahepatic Cholestasis of Pregnancy)?

Obstetric cholestasis, also called intrahepatic cholestasis of pregnancy (ICP), is a liver condition that can develop during pregnancy, usually in the last three months. It causes severe itching, especially on the palms of your hands and soles of your feet, which is often worse at night.

The condition happens because your liver isn't processing bile acids (substances that help digest fats) properly. These bile acids build up in your blood, causing the itching. The condition is diagnosed with a simple blood test.

Why Does It Happen?

During pregnancy, hormones (especially oestrogen and progesterone) increase dramatically. In some women, these hormones interfere with the liver's ability to transport bile acids. Some women also have genetic factors that make them more likely to develop obstetric cholestasis.

What Are the Symptoms?

• Intense itching (especially palms and soles, worse at night)
• No rash (just scratch marks from itching)
• Sometimes dark urine or pale stools
• Occasionally mild yellowing of the eyes (jaundice), though this is uncommon

Is It Dangerous?

For you (the mother), obstetric cholestasis is not dangerous and will go away completely within a few weeks after your baby is born.

However, there is a small risk to your baby. Bile acids can cross the placenta and, in some cases, affect your baby's heart rhythm, leading to a risk of stillbirth (baby dying in the womb). The risk depends on how high your bile acid levels are:

• Low bile acids (less than 40): Very low risk (similar to normal pregnancy)
• Moderate bile acids (40-99): Small increased risk (~1%)
• High bile acids (100 or more): Higher risk (~3-5%)

Because of this risk, your doctors will monitor you closely and may recommend delivering your baby a bit earlier than your due date.

How Is It Diagnosed?

A blood test measures your bile acid levels. If they are higher than 10 (normal is less than 10), you have obstetric cholestasis.

You will also have liver function tests and other blood tests to check your liver and rule out other conditions.

What Treatment Will I Have?

1. Medicine to reduce itching:

   • Ursodeoxycholic acid (UDCA): Tablets that help your liver process bile acids better and reduce itching in about 50-70% of women
   • Creams and lotions: Moisturizing creams or menthol cream for soothing relief
   • Antihistamines: Tablets like chlorphenamine to help with itching and help you sleep

2. Monitoring:

   • Weekly blood tests to check your bile acid levels
   • CTG monitoring (heart rate monitoring) of your baby, usually twice a week
   • Counting baby's movements every day (this is very important—if you notice reduced movements, contact your midwife or maternity unit immediately)

3. Earlier delivery:

   • Depending on your bile acid levels, your doctors will recommend delivering your baby between 37-39 weeks (instead of waiting until 40 weeks)
   • If your bile acids are very high (100 or more), they may recommend delivery even earlier (around 36-37 weeks)
   • Delivery is usually by induction of labour (starting labour artificially), though you can still aim for a vaginal birth

What Happens After My Baby Is Born?

The itching will stop within a few days to a week after delivery. Your bile acid levels and liver tests will return to normal within 2 weeks.

You will have a follow-up blood test about 6-8 weeks after birth to make sure everything has gone back to normal.

Will It Happen Again?

If you get pregnant again, there is a 45-90% chance obstetric cholestasis will come back. If it does, it often starts earlier and may be more severe. Your doctors will monitor you closely from early pregnancy.

What About Contraception?

You should avoid the combined contraceptive pill (the pill containing oestrogen), as oestrogen can trigger itching similar to obstetric cholestasis in some women. Safe options include:

• Progestogen-only pill (mini-pill)
• Contraceptive implant or injection
• IUD (coil)
• Barrier methods (condoms)

Key Takeaways

• Obstetric cholestasis causes severe itching, diagnosed by high bile acid levels in your blood
• It's not dangerous to you, but there is a small risk to your baby (stillbirth)
• Treatment involves medicine (UDCA), creams, and close monitoring
• You will likely be induced between 37-39 weeks to reduce the risk to your baby
• The condition goes away completely after you give birth
• There is a high chance (45-90%) it will happen again in future pregnancies

If you have any concerns, especially if you notice reduced baby movements, contact your midwife or maternity unit immediately.

---

15. References

Primary Guidelines

1. Royal College of Obstetricians and Gynaecologists. Obstetric Cholestasis (Green-top Guideline No. 43). 2011 (updated 2022). Available at: https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/obstetric-cholestasis-green-top-guideline-no-43/

2. Society for Maternal-Fetal Medicine (SMFM). Intrahepatic cholestasis of pregnancy: replaces clinical guideline number 13, April 2011. Am J Obstet Gynecol 2021;224(4):B2-B9. PMID: 33545147 DOI: 10.1016/j.ajog.2021.01.022

Landmark Studies

3. Chappell LC, Bell JL, Smith A, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet 2019;394(10201):849-860. PMID: 31378395 DOI: 10.1016/S0140-6736(19)31270-X

4. Ovadia C, Seed PT, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet 2019;393(10174):899-909. PMID: 30773280 DOI: 10.1016/S0140-6736(18)31877-4

Pathophysiology and Genetics

5. Dixon PH, Williamson C. The pathophysiology of intrahepatic cholestasis of pregnancy. Clin Res Hepatol Gastroenterol 2016;40(2):141-153. PMID: 26823041 DOI: 10.1016/j.clinre.2015.12.008

6. Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol 2014;124(1):120-133. PMID: 24901263 DOI: 10.1097/AOG.0000000000000346

7. Dixon PH, Wadsworth CA, Chambers J, et al. A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. Am J Gastroenterol 2014;109(1):76-84. PMID: 24366236 DOI: 10.1038/ajg.2013.406

8. Nayagam JS, Williamson C, Joshi D, et al. Review article: liver disease in adults with variants in the cholestasis-related genes ABCB4, ABCB11 and ATP8B1. Aliment Pharmacol Ther 2020;52(10):1628-1639. PMID: 33070363 DOI: 10.1111/apt.16111

Clinical Presentation and Diagnosis

9. Kondrackiene J, Beuers U, Kupcinskas L. Clinical and biochemical characteristics of intrahepatic cholestasis of pregnancy. Hepatology 2008;48(4):1274-1281. PMID: 18688882 DOI: 10.1002/hep.22484

10. Reyes H, Sjövall J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann Med 2000;32(2):94-106. PMID: 10766401 DOI: 10.3109/07853890009011759

Management and Treatment

11. Ovadia C, Seed PT, Broad K, et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2021;6(7):547-558. PMID: 33915090 DOI: 10.1016/S2468-1253(21)00074-1

12. Chappell LC, Smith A, Bell JL, et al. Effect of ursodeoxycholic acid versus placebo on perinatal outcomes in women with intrahepatic cholestasis of pregnancy. JAMA Netw Open 2020;3(11):e2024649. PMID: 33284566 DOI: 10.1001/jamanetworkopen.2020.24649

13. Bicocca MJ, Sperling JD, Chauhan SP. Intrahepatic cholestasis of pregnancy: Review of six national and regional guidelines. Eur J Obstet Gynecol Reprod Biol 2018;231:180-187. PMID: 30396107 DOI: 10.1016/j.ejogrb.2018.10.041

Fetal Complications

14. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology 2004;40(2):467-474. PMID: 15368452 DOI: 10.1002/hep.20336

15. Geenes V, Chappell LC, Seed PT, et al. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology 2014;59(4):1482-1491. PMID: 24122873 DOI: 10.1002/hep.26617

16. Miragoli M, Kadir SH, Sheppard MN, et al. A protective antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic fetal heart. Hepatology 2011;54(4):1282-1292. PMID: 21809359 DOI: 10.1002/hep.24511

17. Sepúlveda WH, González C, Cruz MA, et al. Vasoconstrictive effect of bile acids on isolated human placental chorionic veins. Eur J Obstet Gynecol Reprod Biol 1991;42(3):211-215. PMID: 1773763 DOI: 10.1016/0028-2243(91)90222-7

Recurrence and Long-Term Outcomes

18. Rioseco AJ, Ivankovic MB, Manzur A, et al. Intrahepatic cholestasis of pregnancy: a retrospective case-control study of perinatal outcome. Am J Obstet Gynecol 1994;170(3):890-895. PMID: 8141221 DOI: 10.1016/s0002-9378(94)70304-6

19. Williamson C, Hems LM, Goulis DG, et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG 2004;111(7):676-681. PMID: 15198756 DOI: 10.1111/j.1471-0528.2004.00167.x

20. Marschall HU, Wikström Shemer E, Ludvigsson JF, et al. Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study. Hepatology 2013;58(4):1385-1391. PMID: 23564560 DOI: 10.1002/hep.26444

---